Ganesh Naresh, van der Vorst Emiel P C, Spiesshöfer Jens, He Shun, Burgmaier Mathias, Findeisen Hannes, Lehrke Michael, Swirski Filip K, Marx Nikolaus, Kahles Florian
Department of Cardiology, Angiology and Intensive Care Medicine, University Hospital Aachen, Aachen, Germany.
Interdisciplinary Center for Clinical Research (IZKF) and Institute for Molecular Cardiovascular Research (IMCAR), University Hospital Aachen, Aachen, Germany.
Front Cardiovasc Med. 2022 Aug 15;9:943214. doi: 10.3389/fcvm.2022.943214. eCollection 2022.
Despite scientific and clinical advances during the last 50 years cardiovascular disease continues to be the main cause of death worldwide. Especially patients with diabetes display a massive increased cardiovascular risk compared to patients without diabetes. Over the last two decades we have learned that cardiometabolic and cardiovascular diseases are driven by inflammation. Despite the fact that the gastrointestinal tract is one of the largest leukocyte reservoirs of our bodies, the relevance of gut immune cells for cardiovascular disease is largely unknown. First experimental evidence suggests an important relevance of immune cells in the intestinal tract for the development of metabolic and cardiovascular disease in mice. Mice specifically lacking gut immune cells are protected against obesity, diabetes, hypertension and atherosclerosis. Importantly antibody mediated inhibition of leukocyte homing into the gut showed similar protective metabolic and cardiovascular effects. Targeting gut immune cells might open novel therapeutic approaches for the treatment of cardiometabolic and cardiovascular diseases.
尽管在过去50年里科学和临床方面都取得了进步，但心血管疾病仍然是全球主要的死亡原因。尤其是糖尿病患者与非糖尿病患者相比，心血管风险大幅增加。在过去二十年中，我们了解到心脏代谢和心血管疾病是由炎症驱动的。尽管胃肠道是人体最大的白细胞储存库之一，但肠道免疫细胞与心血管疾病的相关性在很大程度上尚不清楚。首个实验证据表明，肠道免疫细胞对小鼠代谢和心血管疾病的发展具有重要意义。特异性缺乏肠道免疫细胞的小鼠可预防肥胖、糖尿病、高血压和动脉粥样硬化。重要的是，抗体介导的白细胞归巢至肠道的抑制显示出类似的代谢和心血管保护作用。靶向肠道免疫细胞可能为治疗心脏代谢和心血管疾病开辟新的治疗方法。
